Issra Jamal, MD
Endocrinology, Diabetes & Metabolism · Springfield, MANPI 1457792871
Payments from drug & device makers
Across 117 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$284
- Amgen$283
- Novo Nordisk$244
- Valeritas, Inc.$161
- AstraZeneca$131
- Corcept Therapeutics$131
- plus $782 from 16 others
What the payments were for
- Food & beverage$1,99299%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 19 | $284 |
| Amgen(2 entities) | 16 | $283 |
| Novo Nordisk | 15 | $244 |
| Valeritas, Inc. | 2 | $161 |
| AstraZeneca | 9 | $131 |
| Corcept Therapeutics | 10 | $131 |
| Mannkind Corporation | 7 | $118 |
| Xeris Pharmaceuticals, Inc. | 6 | $115 |
| Merck | 7 | $95 |
| Sanofi-aventis U.S. LLC | 4 | $66 |
| Radius Health, Inc. | 3 | $60 |
| Amarin Pharma, Inc. | 3 | $53 |
| Boehringer Ingelheim | 3 | $52 |
| Abbott | 3 | $50 |
| Shire North American Group Inc | 3 | $50 |
| Insulet Corporation | 1 | $22 |
| Zealand Pharma US, Inc. | 1 | $21 |
| Tandem Diabetes Care, Inc. | 1 | $21 |
| Vifor Pharma, Inc. | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
| Companion Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- V-GO$139
How this compares
$2,016 in reported general payments places this provider in the 55th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 115 | $130,222 |
| ForteoTeriparatide | 14 | $54,202 |
| ProliaDenosumab | 19 | $32,214 |
| MounjaroTirzepatide | 32 | $31,950 |
| JardianceEmpagliflozin | 43 | $31,772 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $24,615 |
| OzempicSemaglutide | 26 | $22,955 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 21 | $20,076 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $18,925 |
| JanuviaSitagliptin Phosphate | 24 | $15,957 |
| Novolog FlexpenInsulin Aspart | 66 | $14,654 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $13,270 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 81 | $10,116 |
| Praluent PenAlirocumab | 14 | $9,500 |
| Testosterone | 43 | $8,250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Forteo, Mounjaro | $284 | $216,374161 claims |
| AmgenProlia | $283 | $32,21419 claims |
| Boehringer IngelheimJardiance | $52 | $31,77243 claims |
| Novo NordiskOzempic, Novolog | $244 | $28,40652 claims |
| MerckJanuvia | $95 | $15,95724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Springfield
- David NathanBoston$9M
- Vanita ArodaBoston$4.2M
- George KingBoston$3.7M
- Karen MillerBoston$2.9M
- Steven GrinspoonBoston$2.7M
- Jason GagliaBoston$2.5M
- Tamer YacoubFall River$1.4M
- Elaine YuBoston$1.3M
- Osama HamdyBoston$1.1M
- Steven RussellBoston$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.